Predictive Oncology Inc. (POAI): ANSOFF MATRIX [Dec-2025 Updated]

Honestly, seeing Predictive Oncology Inc. (POAI) pivot from pure AI oncology to a dual model means we have four distinct growth lanes to analyze, and you need to know where the risk/reward is best. We're looking at everything from driving current US utilization to boost Q3's $3.6 million revenue, launching ChemoFx® in Europe, tapping the $51.5 billion biomarker market, and actively monetizing their 5.70 billion ATH tokens. This strategy is complex, but the path forward is clear. See the full breakdown below.

Predictive Oncology Inc. (POAI) - Ansoff Matrix: Market Penetration

You're looking at how Predictive Oncology Inc. (POAI) can drive more sales from its existing customer base-the core of market penetration strategy. This means pushing current products like ChemoFx® and PeDAL™ harder into the US oncology practices and biopharma partners already using your services.

The primary lever here is the 92% prediction accuracy of the PEDAL™ platform. That number is what you lead with in any aggressive digital marketing push. You need to translate that high confidence into increased assay utilization across current US oncology practices. For existing biopharma clients, the goal is to boost that Q3 target of $3.6 million revenue, likely through tiered pricing for PeDAL™ platform access.

Your existing asset base is a huge advantage for repeat business. You target current drug discovery partners specifically with the 150,000+ tumor sample biobank for repeat studies. This biobank, containing over 150,000 assay-capable heterogenous human tumor samples, is the foundation for maximizing PeDAL™ value for those partners. Also, remember to cross-sell the CLIA-certified lab services directly to current AI platform users; that's pure penetration.

The recent Sales and marketing expenses reflect this push, coming in at $133,494 for the three months ended September 30, 2025, up from $72,667 in the comparable period in 2024. That increase is partly due to higher fees for digital marketing consultants, which supports the launch of that defintely aggressive digital marketing campaign highlighting the 92% prediction accuracy.

Here's a quick look at the operational numbers supporting this penetration strategy as of the third quarter of 2025:

The company's R&D expense for the quarter was $528,557, which was largely unchanged from the $535,236 reported in the comparable period in 2024. General and administrative expenses saw a larger jump, increasing by $1.1 million to reach $2.6 million in the three months ended September 30, 2025, compared to $1.5 million in Q3 2024.

The digital asset treasury strategy also impacts the financial picture, with the company holding approximately 5.70 billion ATH as of November 10, 2025, valued at approximately $152.8 million. Of that total, 3.7 billion ATH are locked, and 2.0 billion ATH are unlocked.

You should focus on these utilization and revenue drivers:

• Increase ChemoFx® assay utilization rate by 15% quarter-over-quarter.
• Secure new tiered pricing agreements for PeDAL™ targeting $3.6 million in Q3 revenue contribution.
• Drive repeat business using the 150,000+ tumor sample biobank.
• Convert 25% of current AI platform users to utilize CLIA-certified lab services.
• Achieve a 10% increase in qualified leads from the digital marketing campaign.

Predictive Oncology Inc. (POAI) - Ansoff Matrix: Market Development

You're looking at how Predictive Oncology Inc. (POAI) plans to grow by taking its existing products, like ChemoFx®, into new geographical areas or by taking its existing platforms, like PeDAL™, into new therapeutic markets. This is about expansion outside the current core business footprint.

Execute the planned de novo launch of the ChemoFx® assay into the European market

The plan involved a de novo (new) launch of the ChemoFx® assay in Europe, announced in January 2025. This is targeting a market where an estimated 250,000 gynecologic cancer cases are diagnosed annually. The initial focus remains on ovarian and other gynecological cancers, which aligns with the company's biobank concentration-nearly half of the approximately 150,000 live cell tumor samples are gynecological. When first introduced, ChemoFx® generated gross revenues in excess of $25 million annually. The company reported a loss from continuing operations of approximately $2.3 million on total revenue of $110,310 for the first quarter of 2025. By the end of Q2 2025, cash on hand had dropped to $506,078 from $611,822 at the end of 2024, showing the need for capital to fund this expansion.

Expand the PeDAL™ platform's oncology focus beyond ovarian and gynecological cancers to other major tumor types

The PeDAL™ platform, which predicts tumor response with 92% accuracy, is being leveraged to move beyond its initial focus. The strategy includes expanding testing capabilities into other major tumor types, specifically naming breast, colon, and lung cancers. This move taps into the broader biomarker discovery market, which was valued at $14.5 billion in 2024 and is projected to grow at a 19.4% CAGR through 2030. The platform is supported by a biobank containing over 150,000 assay-capable tumor samples across 137 tumor types.

Here's a look at the drug repurposing exploration tied to this platform expansion:

• Identified three compounds warranting further exploration in new colon and breast tumor indications in Q1 2025.
• Specific compounds noted were Afuresertib (breast), Alisertib (colon), and Entinosta (colon).
• The company also developed two distinct 3D liver toxicity models exclusively for Labcorp during Q2 2025.

Partner with government or non-profit research consortia to access new funding markets

While specific government or non-profit consortium funding market access numbers aren't detailed, business development efforts are clearly underway to secure external validation and funding streams. The company reported entering into a standby equity purchase agreement (SEPA) in July 2025, which provides access to up to $10 million in funding. Furthermore, the company has been actively engaged in studies, such as the one with UPMC Magee-Womens Hospital, which yielded AI-powered survival prediction models.

Secure initial contracts for AI-driven drug discovery services in the Asia-Pacific region

Specific financial figures for initial contracts in the Asia-Pacific region were not reported in the available 2025 data. However, the overall business development focus is on leveraging the PEDAL platform for biopharma clients to prioritize their oncology portfolios. The company's AI platform is designed to offer unique financial- and time-saving advantages for pharmaceutical companies.

Leverage the Nasdaq compliance status to attract larger, international institutional investors

Regaining compliance with Nasdaq Listing Rule 5550(b)(1) by meeting the minimum stockholders' equity requirement of $2,500,000 on December 1, 2025, is a key step for investor confidence. This compliance followed significant capital activity in October 2025, where the company closed private investment in public equity (PIPE) transactions totaling approximately $343.5 million. This raise included about $50.8 million in cash and in-kind contributions of crypto assets valued at a discounted amount of roughly $173.3 million. The stock was trading at $5.45 on December 2, 2025. The company is also implementing a digital asset treasury strategy, planning to use $44.5 million net cash to purchase ATH tokens, targeting high single-digit returns by FY'26.

Here's a summary of the financial strengthening events supporting investor attraction:

The company reported a substantial net loss in Q3 2025, yet this capital infusion and compliance maintenance are designed to support these aggressive Market Development initiatives.

Predictive Oncology Inc. (POAI) - Ansoff Matrix: Product Development

You're looking at how Predictive Oncology Inc. (POAI) can grow by creating new offerings for its existing customer base, which is a key part of the Product Development strategy. The company's recent financial performance shows a loss from continuing operations of approximately $2.0 million for the quarter ended June 30, 2025, on revenue of $2,682 for that same quarter. This compares to Q1 2025 revenue of $110,310 and a loss from continuing operations of approximately $2.3 million.

The core of this product development push involves commercializing and expanding the use of proprietary technologies developed under existing agreements.

Commercializing Advanced Toxicity Models

Predictive Oncology Inc. successfully developed two distinct and unique 3D liver toxicity models exclusively for Labcorp, including a human model and a rat model. Labcorp, a healthcare services giant with annual revenues exceeding $13 billion, is committed to using these new approach methodologies (NAMs) in preclinical studies. The goal here is to take this validated technology, which provides species-specific data for both human and rat liver environments, and offer it to the broader toxicology market. The global Toxicology Testing Services Market was accounted for at $41.24 billion in 2025. The Toxicology Drug Screening Market specifically was expected to reach $15.78 billion in 2025.

Launching New Biomarker Discovery Services

A major opportunity lies in launching new biomarker discovery services. The overall global biomarkers market size was estimated at $85.9 billion in 2025. Focusing specifically on outsourcing, the global biomarker discovery outsourcing services market size was estimated at $14.53 billion in 2024 and is projected to reach $41.27 billion by 2030. Predictive Oncology Inc. (POAI) can position its AI/ML capabilities to capture a share of this growth, driven by the demand for personalized medicine.

Introducing AI-Driven Drug Repurposing Subscriptions

The collaboration with Every Cure forms the basis for a potential subscription service offering real-time access to AI-generated drug repurposing candidates. This effort leverages Predictive Oncology Inc.'s platform, PEDAL, which reportedly predicts patient tumor drug response with 92% accuracy. The initial screening involves testing approximately 150 FDA-approved drugs against the company's biobank of more than 150,000 assay-capable heterogenous human tumor samples.

Next-Generation AI Model Development and Service Offerings

Product development also includes internal R&D to enhance the core technology. This involves developing a next-generation AI model specifically designed to predict drug response in combination therapies, moving beyond single-agent predictions. Furthermore, the company can monetize its existing infrastructure by offering customized AI model training services using client-specific data directly within its wholly owned CLIA laboratory facility.

Here's a look at the market context for these product expansions:

The immediate product focus areas for Predictive Oncology Inc. include:

• Commercializing human and rat 3D liver toxicity models.
• Launching services targeting the biomarker discovery outsourcing market.
• Monetizing the Every Cure partnership via a subscription model.
• Advancing the PEDAL platform's predictive accuracy beyond 92%.
• Leveraging the CLIA lab for bespoke client data training services.

Finance: draft 13-week cash view by Friday.

Predictive Oncology Inc. (POAI) - Ansoff Matrix: Diversification

Actively monetize the 5.70 billion ATH tokens held to generate booked revenue from AI compute.

Predictive Oncology Inc. (POAI) held approximately 5.70 billion ATH as of November 10, 2025. The market value of this holding was approximately $152.8 million based on a price of $0.0268 per ATH on that date.

The deployment of these assets is structured to generate booked revenue through the Aethir network, leveraging the decentralized GPU power for enterprise deployments.

The breakdown of the digital asset treasury as of November 10, 2025, is detailed below:

Establish the Strategic Compute Reserve as a revenue-generating AI infrastructure service for non-oncology enterprises.

The Strategic Compute Reserve is positioned to help stimulate and onboard supply while satisfying enterprise demand for compute, utilizing the native ATH token to unlock capacity. This initiative is intended to generate booked revenue and cash earnings. The strategy was launched following two private placements closing on October 7, 2025, which totaled approximately $343.5 million, including in-kind contributions of ATH.

Achieve the stated goal of a high single-digit yield on the $152.8 million market value of ATH tokens by 2026.

The target is to achieve a high single-digit yield on the ATH tokens for fiscal year 2026. This yield is calculated against the market value of approximately $152.8 million as of November 10, 2025. The company aims to monetize these assets through staking and GPU rentals.

Convert unlocked ATH tokens to cash to fund core oncology R&D, reducing the $656,000 monthly cash burn.

The implied monthly cash burn averages to $656,000. The cash and cash equivalents from continuing operations concluded Q3 2025 at $181,667, down from $611,822 on December 31, 2024. The net cash used in operating activities of continuing operations for the nine months ended September 30, 2025, was $5.9 million, a reduction of 26% from $8.0 million in the prior year period.

Key financial metrics related to operational funding include:

• Net cash used in operating activities (9 months YTD 2025): $5.9 million.
• Cash and cash equivalents (End Q3 2025): $181,667.
• Monthly cash burn (Implied average): $656,000.
• Revenue (Q3 2025): $3,618.
• Net Loss (Q3 2025): $77.7 million.

Form new partnerships to deploy the Aethir network's decentralized GPU power for general AI applications.

The digital asset treasury strategy was launched in partnership with DNA Holdings. The strategy involves utilizing the 2.0 billion unlocked ATH to function as an operator on the Aethir ecosystem. The overall strategy is intended to scale beyond oncology applications by developing systems for real enterprise deployments.